| Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ... The Lancet Oncology 21 (2), 271-282, 2020 | 1348 | 2020 |
| Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020 | 666 | 2020 |
| Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers VWS Wong, SL Chan, F Mo, TC Chan, HHF Loong, GLH Wong, YYN Lui, ... Journal of clinical oncology 28 (10), 1660-1665, 2010 | 511 | 2010 |
| NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act. In … S Bonvalot, PL Rutkowski, J Thariat, S Carrère, A Ducassou, MP Sunyach, ... The Lancet Oncology 20 (8), 1148-1159, 2019 | 359 | 2019 |
| Overview of current systemic management of EGFR-mutant NSCLC WH Hsu, JCH Yang, TS Mok, HH Loong Annals of Oncology 29, i3-i9, 2018 | 292 | 2018 |
| Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial ATC Chan, EP Hui, RKC Ngan, SY Tung, ACK Cheng, WT Ng, VHF Lee, ... Journal of clinical oncology 36 (31), 3091-3100, 2018 | 213 | 2018 |
| Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma MM Gounder, A Zer, WD Tap, S Salah, MA Dickson, AA Gupta, ... Journal of Clinical Oncology 34 (26), 3166-3174, 2016 | 156 | 2016 |
| A phase II study of concurrent cetuximab–cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma BBY Ma, MKM Kam, SF Leung, EP Hui, AD King, SL Chan, F Mo, H Loong, ... Annals of oncology 23 (5), 1287-1292, 2012 | 153 | 2012 |
| COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials A Desai, JF Gainor, A Hegde, AM Schram, G Curigliano, S Pal, SV Liu, ... Nature reviews Clinical oncology 18 (5), 313-319, 2021 | 150 | 2021 |
| A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. AE Drilon, V Subbiah, GR Oxnard, TM Bauer, V Velcheti, NJ Lakhani, ... Journal of Clinical Oncology 36 (15_suppl), 102-102, 2018 | 129 | 2018 |
| Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma HH Loong, BBY Ma, SF Leung, F Mo, EP Hui, MK Kam, SL Chan, ... Radiotherapy and Oncology 104 (3), 300-304, 2012 | 128 | 2012 |
| Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation EP Hui, BBY Ma, AD King, F Mo, SL Chan, MKM Kam, HH Loong, ... Annals of oncology 22 (6), 1280-1287, 2011 | 128 | 2011 |
| Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)-a correlative study to explore potential biomarkers for response W Yeo, SL Chan, FKF Mo, CM Chu, JWY Hui, JHM Tong, AWH Chan, ... BMC cancer 15, 1-11, 2015 | 119 | 2015 |
| PL02. 08 registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers A Drilon, G Oxnard, L Wirth, B Besse, O Gautschi, SWD Tan, H Loong, ... Journal of Thoracic Oncology 14 (10), S6-S7, 2019 | 102 | 2019 |
| Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer CWS Tong, WKK Wu, HHF Loong, WCS Cho, KKW To Cancer letters 405, 100-110, 2017 | 93 | 2017 |
| Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial A Drilon, V Subbiah, O Gautschi, P Tomasini, F De Braud, BJ Solomon, ... Journal of Clinical Oncology 41 (2), 385-394, 2023 | 90 | 2023 |
| Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer HH Loong, BB Ma, AT Chan Hematology/oncology clinics of North America 22 (6), 1267-1278, 2008 | 90 | 2008 |
| Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma HH Loong, W Yeo OncoTargets and therapy, 575-585, 2014 | 78 | 2014 |
| Intracranial efficacy of selpercatinib in RET fusion-positive non–small cell lung cancers on the LIBRETTO-001 trial V Subbiah, JF Gainor, GR Oxnard, DSW Tan, DH Owen, BC Cho, ... Clinical Cancer Research 27 (15), 4160-4167, 2021 | 72 | 2021 |
| Ceritinib plus nivolumab in patients with advanced ALK-rearranged non–small cell lung cancer: results of an open-label, multicenter, phase 1B study E Felip, FG de Braud, M Maur, HH Loong, AT Shaw, JF Vansteenkiste, ... Journal of Thoracic Oncology 15 (3), 392-403, 2020 | 61 | 2020 |
